Multilocus genetic interactions and response to efavirenz-containing regimens: An Adult AIDS Clinical Trials Group study

Pharmacogenetics and Genomics

Volumn 16, Issue 11, 2006, Pages 837-845

  Motsinger, Alison A ^a   Ritchie, Marylyn D ^a   Shafer, Robert W ^b   Robbins, Gregory K ^d   Morse, Gene D ^e   Labbé, Line ^h   Wilkinson, Grant R ^a   Clifford, David B ^f   D'Aquila, Richard T ^a   Johnson, Victoria A ^g   Pollard, Richard B ^c   Merigan, Thomas C ^e   Hirsch, Martin S ^d   Donahue, John P ^a   Kim, Richard B ^a   Haas, David W ^a,i  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HIV therapy efavirenz; Multifactor dimensionality reduction; Pharmacogenomics

Indexed keywords

ABC TRANSPORTER A1; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PLACEBO; STAVUDINE;

AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT FAILURE; TREATMENT RESPONSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, GENETIC; OXAZINES; TREATMENT FAILURE; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33750312905     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000230413.97596.fa     Document Type: Article

References (52)

1. The Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated 6 May 2006. Available at: http://aidsinfo.nih.gov/ guidelines/[Accessed 26 May 2006].
2. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-1873.
3. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-721.
4. Haas DW, Ribaudo HJ, Kim RB, Tierney C,Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400.
5. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287-300.
6. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group study. J Infect Dis 2005; 192:1931-1942.
7. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
8. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19:1038-1045.
9. Sing CF, Stengard JH, Kardia SL. Dynamic relationships between the genome and exposures to environments as causes of common human diseases. World Rev Nutr Diet 2004; 93:77-91.
10. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 2003; 56:73-82.
11. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 2004; 20:640-647.
12. Moore JH, Williams SM. New strategies for identifying gene-gene interactions in hypertension. Ann Med 2002; 34:88-95.
13. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69:138-147.
14. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109:1640-1646.
15. Motsinger AA, Donahue BS, Brown NJ, Roden DM, Ritchie MD. Risk factor interactions and genetic effects associated with post-operative atrial fibrillation. Pac Symp Biocomputing 2006; 11:584-595.
16. Shafer RW, Smeaton LM, Robbins GK, De GV, Snyder SW, D'Aquila RT, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304-2315.
17. Haas DW,Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, Mahon LF, et al. A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG protocol A5128. HIV Clin Trials 2003; 4/5:287-300.
18. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
19. Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003; 24:150-157.
20. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19:376-382.
21. Weiss GM, Provost F. Learning when training data are costly: the effect of class distribution on tree induction. J Artif Intell Res 2003; 19:315-354.
22. Japkowicz N, Stephen S. The class imbalance problem: a systematic study. Intell Data Anal 2002; 6:429-450.
23. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289-294.
24. Almond LM, Hoggard PG, Edirisinghe D, Khoo SH, Back DJ. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56:738-744.
25. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with Pglycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
26. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72:584-594.
27. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003; 58:809-812.
28. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-219.
29. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18:1400-1404.
30. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002; 19:1581-1585.
31. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71:297-303.
32. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54:610-616.
33. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72:572-583.
34. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
35. Song P, Lamba JK, Zhang L, Schuetz E, Shukla N, Meibohm B, et al. G2677T and C3435T Genotype and Haplotype Are Associated With Hepatic ABCB1 (MDR1) Expression. J Clin Pharmacol 2006; 46:373-379.
36. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003; 59:303-312.
37. Chowbay B, Li H, David M, Bun CY, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60:159-171.
38. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
39. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11:399-415.
40. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003; 31:398-403.
41. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
42. Lamba V, Lamba J, Yasuda K, Strom S, Davila JC, Hancock M, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR expression. J Pharmacol Exp Ther 2003; 307:906-922.
43. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 1997; 25:985-993.
44. Stresser DM, Kupfer D. Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 1999; 27:517-525.
45. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6:1-42.
46. Rotger M, Colombo S, Cavassini M, Furrer H, Elzi L, Günthard H, et al. Genetic variability of CYP2B6 in individuals with extremely high efavirenz plasma concentrations. Presented at the 13th Conference on Retroviruses and Opportunistic Infections, February 2006, Denver, Colorado, Abstract 572 2006.
47. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306-309.
48. Bellman R. Adaptive control processes. Princeton: Princeton University Press; 1961.
49. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48:1503-1510.
50. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49:1373-1379.
51. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993; 118:201-210.
52. Moore JH. Computational analysis of gene-gene interactions using multifactor dimensionality reduction. Expert Rev Mol Diagn 2004; 4:795-803.